Avanir Pharmaceuticals, Inc (NASDAQ:AVNR) announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company’s patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications (‘ANDAs’) for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shares after opening at $3.38 moved to $5.15 on last trade day and at the end of the day closed at $ 4.98 . Company price to sales ratio in past twelve months was calculated as 8.86 and price to cash ratio as 17.28. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) showed a positive weekly performance of 43.52%.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) issued a press release announcing that it expects to report financial results for the quarter ending March 31, 2014 after the market closes on May 12, 2014, and will hold a conference call and webcast on May 13, 2014 to review the first quarter 2014 financial results and to provide a business update. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares advanced 8.45% in last trading session and ended the day on $8.21. SUPN return on equity ratio is recorded as -299.70% and its return on assets is -82.80%. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) yearly performance is 59.73%.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)a specialty pharmaceutical company, presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson’s disease treatment. The data, from Adamas’ Phase 2/3 EASED study, included assessments of patients receiving ADS-5102 using a metric called the Clinician’s Global Impression of Change (CGI-C). The clinicians were asked to assess their impression of the change in a subject’s clinical status related to overall Parkinson’s disease, including LID. CGI-C is a tool to evaluate a patient’s response over time and is routinely used for a number of diseases, including Parkinson’s disease. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares moved up 15.31% in last trading session and was closed at $18.45 while trading in range of $16.00 – $19.11 – Adamas Pharmaceuticals Inc (NASDAQ:ADMS) year to date (YTD) performance is 31.69%.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced that clinical and preclinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 30 to June 3, 2014 in Chicago, Illinois. Clinical results to be presented include updated data from Karyopharm’s Phase 1 studies in patients with advanced hematologic malignancies, solid tumors and sarcomas. Karyopharm will host an investor and analyst briefing Monday, June 2, 2014 in Chicago, Illinois at 6:30 p.m. CT. Karyopharm Therapeutics Inc (NASDAQ:KPTI) on last trading day company shares ended up $26.83. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average (SMA50) is -24.45%. Analysts mean target price for the company is $48.25.
Leave a Reply